Determination of human serum α1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors

Current Medicinal Chemistry

Volumn 16, Issue 16, 2009, Pages 1964-1977

  Zsila, Ferenc ^a   Fitos, Ilona ^a   Bencze, Gyula ^b,c   Kéri, György ^b,c   Orfi, László ^b,c  

^a CHEMICAL RESEARCH CENTER   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Vichem Chemie Ltd   (Hungary)

Author keywords

Acute phase proteins; Human serum 1 acid glycoprotein; Human serum albumin; Induced circular dichroism; Plasma protein binding; Tyrosine kinase inhibitors

Indexed keywords

6,7 DIMETHYL 2 PHENYLQUINOXALINE; 7 HYDROXYSTAUROSPORINE; DASATINIB; ERLOTINIB; GEFITINIB; HUMAN SERUM ALBUMIN; IMATINIB; LAPATINIB; NILOTINIB; OROSOMUCOID; PROTEIN KINASE INHIBITOR; SORAFENIB; SUNITINIB; VANDETANIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; AFFINITY CHROMATOGRAPHY; ANTINEOPLASTIC ACTIVITY; BETA SHEET; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CIRCULAR DICHROISM; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYDROPHOBICITY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; PANCREAS CANCER; PROTEIN STRUCTURE; REVIEW; SPECTROSCOPY;

ANIMALS; HUMANS; MARKETING; OROSOMUCOID; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; SERUM ALBUMIN;

EID: 68449098174     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788682191     Document Type: Review

References (89)

1. Mischke, R.; Waterston, M.; Eckersall, P. D. Changes in C-reactive protein and haptoglobin in dogs with lymphatic neoplasia. Vet. J., 2007, 174, 188-192.
2. Kremer, J. M.; Wilting, J.; Janssen, L. H. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev., 1988, 40, 1-47.
3. Peters, T. (1996) All About Albumin: Biochemistry, Genetics, and Medical Applications. San Diego, Academic Press.
4. Duche, J. C.; Urien, S.; Simon, N.; Malaurie, E.; Monnet, I.; Barre, J. Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer. Clin. Biochem., 2000, 33, 197-202.
5. Gundogdu, M.; Kaya, H.; Gulcin, I.; Erdem, F.; Cayir, K.; Keles, M.; Yilmaz, A. Oxidase activity of ceruloplasmin and some acute phase reactant and trace element concentrations in serum of patients with chronic lymphocytic leukemia. Scott. Med. J., 2007, 52, 24-27.
6. Tsavaris, N.; Kosmas, C.; Kopterides, P.; Tsikalakis, D.; Skopelitis, H.; Sakelaridi, F.; Papadoniou, N.; Tzivras, M.; Balatsos, V.; Koufos, C.; Archimandritis, A. Retinol-binding protein, acute phase reactants and Helicobacter pylori infection in patients with gastric adenocarcinoma. World J. Gastroenterol., 2005, 11, 7174-7178.
7. Kremmer, T.; Szollosi, E.; Boldizsár, M.; Vincze, B.; Ludányi, K.; Imre, T.; Schlosser, G.; Vékey, K. Liquid chromatographic and mass spectrometric analysis of human serum acid alpha-1-glycoprotein. Biomed. Chromatogr., 2004, 18, 323-329.
8. Onate-Ocana, L. F.; Aiello-Crocifoglio, V.; Gallardo-Rincon, D.; Herrera-Goepfert, R.; Brom-Valladares, R.; Carrillo, J. F.; Cervera, E.; Mohar-Betancourt, A. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann. Surg. Oncol., 2007, 14, 381-389.
9. Uslu, C.; Taysi, S.; Akcay, F.; Sutbeyaz, M. Y.; Bakan, N. Serum free and bound sialic acid and alpha-1-acid glycoprotein in patients with laryngeal cancer. Ann. Clin. Lab. Sci., 2003, 33, 156-159.
10. Waldmann, T.; Trier, J.; Fallon, H. Albumin metabolism in patients with lymphoma. J. Clin. Invest., 1963, 42, 171-178.
11. Herve, F.; Duche, J. C.; Jaurand, M. C. Changes in expression and microheterogeneity of the genetic variants of human alpha1-acid glycoprotein in malignant mesothelioma. J. Chromatogr. B Biomed. Sci. Appl., 1998, 7 15, 111-123.
12. Sandoval, J. A.; Turner, K. E.; Hoelz, D. J.; Rescorla, F. J.; Hickey, R. J.; Malkas, L. H. Serum protein profiling to identify high-risk neuroblastoma: Preclinical relevance of blood-based biomarkers. J. Surg. Res., 2007, 142, 268-274.
13. Abramson, F. P.; Jenkins, J.; Ostchega, Y. Effects of cancer and its treatments on plasma concentration of alpha 1-acid glycoprotein and propranolol binding. Clin. Pharmacol. Ther., 1982, 32, 659-663.
14. Rasouli, M.; Okhovatian, A.; Enderami, A. Serum proteins profile as an indicator of malignancy: Multivariate logistic regression and ROC analyses. Clin. Chem. Lab. Med., 2005, 43, 913-918.
15. Fiorenza, A. M.; Branchi, A.; Sommariva, D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J. Clin. Lab Res., 2000, 30, 141-145.
16. Israili, Z. H.; Dayton, P. G. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab. Rev., 2001, 33, 161-235.
17. Otagiri, M. A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab. Pharmacokinet., 2005, 20, 309-323.
18. Fuse, E.; Kuwabara, T.; Sparreboom, A.; Sausville, E. A.; Figg, W. D. Review of UCN-01 development: A lesson in the importance of clinical pharmacology. J. Clin. Pharmacol., 2005, 45, 394-403.
19. Fitos, I.; Visy, J.; Zsila, F.; Mády, G.; Simonyi, M. Selective binding of imatinib to the genetic variants of human alpha1-acid glycoprotein. Biochim. Biophys. Acta, 2006, 1760, 1704-1712.
20. Steele, W. H.; Haughton, D. J.; Barber, H. E. Binding of vinblastine to recrystallized human alpha 1-acid glycoprotein. Cancer Chemother. Pharmacol., 1982, 10, 40-42.
21. Azuma, M.; Nishioka, Y.; Aono, Y.; Inayama, M.; Makino, H.; Kishi, J.; Shono, M.; Kinoshita, K.; Uehara, H.; Ogushi, F.; Izumi, K.; Sone, S. Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J. Respir. Crit. Care Med., 2007, 176, 1243-1250.
22. Zsila, F.; Visy, J.; Mády, G.; Fitos, I. Selective plasma protein binding of antimalarial drugs to alpha1-acid glycoprotein. Bioorg. Med. Chem., 2008, 16, 3759-3772.
23. Curtin, N. J.; Barlow, H. C.; Bowman, K. J.; Calvert, A. H.; Davison, R.; Golding, B. T.; Huang, B.; Loughlin, P. J.; Newell, D. R.; Smith, P. G.; Griffin, R. J. Resistance-modifying agents. 11.(1) Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to alpha1-acid glycoprotein. J. Med. Chem., 2004, 47, 4905-4922.
24. Lee, S. Y.; Lim, J. W.; Kim, Y. M. Effect of alpha1-acid glycoprotein expressed in cancer cells on malignant characteristics. Mol. Cells, 2001, 11, 341-345.
25. Finlay, G. J.; Baguley, B. C. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Cancer Chemother. Pharmacol., 2000, 45, 417-422.
26. Vita, M.; Abdel-Rehim, M.; Nilsson, C.; Hassan, Z.; Skansen, P.; Wan, H.; Meurling, L.; Hassan, M. Stability, pKa and plasma protein binding of roscovitine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2005, 821, 75-80.
27. Evans, S. M.; Robertson, I. G.; Paxton, J. W. Plasma protein binding of the experimental antitumour agent acridine-4-carboxamide in man, dog, rat and rabbit. J. Pharm. Pharmacol., 1994, 46, 63-67.
28. Tang, K.; Qin, Y. M.; Lin, A. H.; Hu, X.; Zou, G. L. Interaction of daunomycin antibiotic with human serum albumin: Investigation by resonant mirror biosensor technique, fluorescence spectroscopy and molecular modeling methods. J. Pharm. Biomed. Anal., 2005, 39, 404-410.
29. Chassany, O.; Urien, S.; Claudepierre, P.; Bastian, G.; Tillement, J. P. Comparative serum protein binding of anthracycline derivatives. Cancer Chemother. Pharmacol., 1996, 38, 571-573.
30. Katsuki, M.; Chuang, V. T.; Nishi, K.; Suenaga, A.; Otagiri, M. Tryptophan residues play an important role in the extraordinarily high affinity binding interaction of UCN-01 to human alpha-1-acid glycoprotein. Pharm. Res., 2004, 21, 1648-1655.
31. Li, J.; Brahmer, J.; Messersmith, W.; Hidalgo, M.; Baker, S. D. Binding of gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest. New Drugs, 2006, 24, 291-297
32. Urien, S.; Bastian, G.; Lucas, C.; Bizzari, J. P.; Tillement, J. P. Binding of a new vinca alkaloid derivative, S12363, to human plasma proteins and platelets. Usefulness of an erythrocyte partitioning technique. Invest. New Drugs, 1992, 10, 263-268
33. Malumbres, M.; Barbacid, M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci., 2005, 30, 630-641.
34. Cohen, P. Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov., 2002, 1, 309-315
35. Chaparro, M.; Gonzalez Moreno, L.; Trapero-Marugan, M.; Medina, J.; Moreno-Otero, R. Review article: Pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment. Pharmacol. Ther., 2008, 28, 1269-1277.
36. Eustace, A. J.; Crown, J.; Clynes, M.; O'Donovan, N. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J. Transl. Med., 2008, 6, 53.
37. Socinski, M. A. The current status and evolving role of sunitinib in non-small cell lung cancer. J. Thorac. Oncol., 2008, 3, S119-123.
38. Raymond, E.; Faivre, S.; Armand, J. P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs, 2000, 60 Suppl 1, 15-23; discussion 41-12.
39. Quintas-Cardama, A.; Cortes, J. Nilotinib: A phenylaminopyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. Future Oncol., 2008, 4, 611-621.
40. Nelson, M. H.; Dolder, C. R. Lapatinib: A novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann. Pharmacother., 2006, 40, 261-269.
41. Widmer, N.; Decosterd, L. A.; Csajka, C.; Leyvraz, S.; Duchosal, M. A.; Rosselet, A.; Rochat, B.; Eap, C. B.; Henry, H.; Biollaz, J.; Buclin, T. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J. Clin. Pharmacol., 2006, 62, 97-112.
42. Calvo, R.; Lukas, J. C.; Rodriguez, M.; Leal, N.; Suarez, E. The role of unbound drug in pharmacokinetics/pharmacodynamics and in therapy. Curr Pharm Des, 2006, 12, 977-987.
43. Baker, S. D.; van Schaik, R. H.; Rivory, L. P.; Ten Tije, A. J.; Dinh, K.; Graveland, W. J.; Schenk, P. W.; Charles, K. A.; Clarke, S. J.; Carducci, M. A.; McGuire, W. P.; Dawkins, F.; Gelderblom, H.; Verweij, J.; Sparreboom, A. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin. Cancer Res., 2004, 10, 8341-8350.
44. Ceciliani, F.; Pocacqua, V. The acute phase protein alpha1-acid glycoprotein: A model for altered glycosylation during diseases. Curr. Protein Pept. Sci, 2007, 8, 91-108.
45. Tomei, L.; Eap, C. B.; Baumann, P.; Dente, L. Use of transgenic mice for the characterization of human alpha 1-acid glycoprotein (orosomucoid) variants. Hum. Genet., 1989, 84, 89-91.
46. Dente, L.; Pizza, M. G.; Metspalu, A.; Cortese, R. Structure and expression of the genes coding for human alpha 1-acid glycoprotein. EMBO J., 1987, 6, 2289-2296.
47. Herve, F.; Caron, G.; Duche, J. C.; Gaillard, P.; Abd Rahman, N.; Tsantili-Kakoulidou, A.; Carrupt, P. A.; d'Athis, P.; Tillement, J. P.; Testa, B. Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: Generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant. Mol. Pharmacol., 1998, 54, 129-138.
48. Kopecky, V., Jr.; Ettrich, R.; Hofbauerova, K.; Baumruk, V. Structure of human alpha1-acid glycoprotein and its high-affinity binding site. Biochem. Biophys. Res. Commun., 2003, 300, 41-46.
49. Schlehuber, S.; Skerra, A. Lipocalins in drug discovery: From natural ligand-binding proteins to "anticalins". Drug Discov. Today, 2005, 10, 23-33.
50. 1-acid glycoprotein (orosomucoid) solved by UV RIP reveals the broad drug-binding activity of this human plasma lipocalin. J. Mol. Biol., 2008, 384, 393-405.
51. Fournier, T.; Medjoubi, N. N.; Porquet, D. Alpha-1-acid glycoprotein. Biochim. Biophys. Acta, 2000, 1482, 157-171.
52. Rahman, M. M.; Miranda-Ribera, A.; Lecchi, C.; Bronzo, V.; Sartorelli, P.; Franciosi, F.; Ceciliani, F. Alpha(1)-acid glycoprotein is contained in bovine neutrophil granules and released after activation. Vet. Immunol. Immunopathol., 2008.
53. Martinez Cordero, E.; Gonzalez, M. M.; Aguilar, L. D.; Orozco, E. H.; Hernandez Pando, R. Alpha-1-acid glycoprotein, its local production and immunopathological participation in experimental pulmonary tuberculosis. Tuberculosis (Edinb.), 2008, 88, 203-211.
54. Hochepied, T.; Berger, F. G.; Baumann, H.; Libert, C. Alpha(1)-acid glycoprotein: An acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev., 2003, 14, 25-34.
55. Logdberg, L.; Wester, L. Immunocalins: A lipocalin subfamily that modulates immune and inflammatory responses. Biochim. Biophys. Acta, 2000, 1482, 284-297.
56. Zsila, F. Overlapping ligand specificity of P-glycoprotein and serum alpha(1)-acid glycoprotein: Evidences and potential implications. Curr. Drug Metab., 2007, 8, 563-593.
57. Albani, J. R. Progesterone binding to the tryptophan residues of human alpha1-acid glycoprotein. Carbohydr. Res., 2006, 341, 2557-2564.
58. Heikinheimo, O.; Kekkonen, R.; Lahteenmaki, P. The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception, 2003, 68, 421-426.
59. Hazai, E.; Visy, J.; Fitos, I.; Bikadi, Z.; Simonyi, M. Selective binding of coumarin enantiomers to human alpha1-acid glycoprotein genetic variants. Bioorg. Med. Chem., 2006, 14, 1959-1965.
60. Fitos, I.; Visy, J.; Zsila, F.; Bikadi, Z.; Mady, G.; Simonyi, M. Specific ligand binding on genetic variants of human alpha1-acid glycoprotein studied by circular dichroism spectroscopy. Biochem. Pharmacol., 2004, 67, 679-688.
61. Nishi, K.; Fukunaga, N.; Otagiri, M. Construction of expression system for human alpha 1-acid glycoprotein in Pichia pastoris and evaluation of its drug-binding properties. Drug Metab. Dispos., 2004, 32, 1069-1074.
62. Hanada, K.; Ohta, T.; Hirai, M.; Arai, M.; Ogata, H. Enantioselective binding of propranolol, disopyramide, and verapamil to human alpha(1)-acid glycoprotein. J. Pharm. Sci., 2000, 89, 751-757.
63. Taheri, S.; Cogswell, L. P., 3rd; Gent, A.; Strichartz, G. R. Hydrophobic and ionic factors in the binding of local anesthetics to the major variant of human alpha1-acid glycoprotein. J. Pharmacol. Exp. Ther., 2003, 304, 71-80.
64. Zsila, F.; Iwao, Y. The drug binding site of human alpha1-acid glycoprotein: Insight from induced circular dichroism and electronic absorption spectra. Biochim. Biophys. Acta, 2007, 1770, 797-809.
65. Zsila, F.; Bikádi, Z.; Fitos, I.; Simonyi, M. Probing protein binding sites by circular dichroism spectroscopy. Curr. Drug Discov. Technol., 2004, 1, 133-153.
66. Zsila, F.; Matsunaga, H.; Bikádi, Z.; Haginaka, J. Multiple ligand-binding properties of the lipocalin member chicken alpha1-acid glycoprotein studied by circular dichroism and electronic absorption spectroscopy: The essential role of the conserved tryptophan residue. Biochim. Biophys. Acta, 2006, 1760, 1248-1273.
67. Fitos, I.; Visy, J.; Zsila, F.; Mády, G.; Simonyi, M. Conformation selectivity in the binding of diazepam and analogues to alpha1-acid glycoprotein. Bioorg. Med. Chem., 2007, 15, 4857-4862.
68. Zsila, F.; Bikádi, Z.; Hazai, E.; Simon, A.; Fitos, I.; Mády, G. Organogold complexes probe a large beta-barrel cavity for human serum alpha1-acid glycoprotein. Biochim. Biophys. Acta, 2008, 1784, 1106-1114.
69. Zsila, F.; Bikádi, Z.; Simonyi, M. Probing the binding of the flavonoid, quercetin to human serum albumin by circular dichroism, electronic absorption spectroscopy and molecular modelling methods. Biochem. Pharmacol., 2003, 65, 447-456.
70. Fitos, I.; Tegyey, Z.; Simonyi, M.; Sjöholm, I.; Larsson, T.; Lagercrantz, C. Stereoselective binding of 3-acetoxy-, and 3-hydroxy-1,4-benzodiazepine-2-ones to human serum albumin. Selective allosteric interaction with warfarin enantiomers. Biochem. Pharmacol., 1986, 35, 263-269.
71. Dufour, C.; Dangles, O. Flavonoid-serum albumin complexation: determination of binding constants and binding sites by fluorescence spectroscopy. Biochim. Biophys. Acta, 2005, 1721, 164-173.
72. Rugo, H. S.; Herbst, R. S.; Liu, G.; Park, J. W.; Kies, M. S.; Steinfeldt, H. M.; Pithavala, Y. K.; Reich, S. D.; Freddo, J. L.; Wilding, G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J. Clin. Oncol., 2005, 23, 5474-5483.
73. Messersmith, W.; Krishnamurthi, S.; Hewes, B.; Zacharchuk, C.; Abbas, R.; Martins, P.; Dowling, E.; Volkert, A.; Martin, E.; Daud, A. Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors. J. Clin. Oncol. (Meeting Abstracts), 2007, 25, 3552.
74. Zinner, R. G.; Nemunaitis, J.; Eiseman, I.; Shin, H. J.; Olson, S. C.; Christensen, J.; Huang, X.; Lenehan, P. F.; Donato, N. J.; Shin, D. M. Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer. Clin. Cancer Res., 2007, 13, 3006-3014.
75. Christopher, L. J.; Cui, D.; Wu, C.; Luo, R.; Manning, J. A.; Bonacorsi, S. J.; Lago, M.; Allentoff, A.; Lee, F. Y.; McCann, B.; Galbraith, S.; Reitberg, D. P.; He, K.; Barros, A., Jr.; Blackwood-Chirchir, A.; Humphreys, W. G.; Iyer, R. A. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab. Dispos., 2008, 36, 1357-1364.
76. Kamath, A. V.; Wang, J.; Lee, F. Y.; Marathe, P. H. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): A potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother. Pharmacol., 2008, 61, 365-376.
77. Product Information: TARCEVA (erlotinib) oral tablets. (2007) OSI Pharmaceuticals, Inc., Melville, NY, 11747, USA.
78. Zhai, S.; Sausville, E. A.; Senderowicz, A. M.; Ando, Y.; Headlee, D.; Messmann, R. A.; Arbuck, S.; Murgo, A. J.; Melillo, G.; Fuse, E.; Figg, W. D. Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms. Anticancer Drugs, 2003, 14, 125-135.
79. US Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Application No. 021399. Clinical Pharmacology and Biopharmaceutics Review. http://www.fda.gov/ cder/foi/nda/2003/21-399_IRESSA_Clinr.pdf
80. US Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Application No. 021588. Clinical Pharmacology and Biopharmaceutics Review. http://www.fda.gov/ cder/foi/nda/2003/021588s000_Gleevec_BioPharmR.pdf
81. US Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Application No. 022068. Clinical Pharmacology and Biopharmaceutics Review. http://www.fda.gov/ cder/foi/nda/2007/022068s000_ClinPharmR.pdf
82. US Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Application No. 021923. Clinical Pharmacology and Biopharmaceutics Review (http://www.fda.gov/ cder/foi/nda/2005/021923_s000_Nexavar_BioPharmR.pdf).
83. US Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Application No. 021938 & 021968. Clinical Pharmacology and Biopharmaceutics Review. http://www.fda.gov/cder/foi/nda/2006/ 021938_S000_Sutent_BioPharmR.pdf
84. Ellis, A. G.; Doherty, M. M.; Walker, F.; Weinstock, J.; Nerrie, M.; Vitali, A.; Murphy, R.; Johns, T. G.; Scott, A. M.; Levitzki, A.; McLachlan, G.; Webster, L. K.; Burgess, A. W.; Nice, E. C. Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochem. Pharmacol., 2006, 71, 1422-1434.
85. Holden, S. N.; Eckhardt, S. G.; Basser, R.; de Boer, R.; Rischin, D.; Green, M.; Rosenthal, M. A.; Wheeler, C.; Barge, A.; Hurwitz, H. I. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann. Oncol., 2005, 16, 1391-1397.
86. Gustafson, D. L.; Bradshaw-Pierce, E. L.; Merz, A. L.; Zirrolli, J. A. Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing. J. Pharmacol. Exp. Ther., 2006, 318, 872-880.
87. Mross, K.; Drevs, J.; Muller, M.; Medinger, M.; Marme, D.; Hennig, J.; Morgan, B.; Lebwohl, D.; Masson, E.; Ho, Y. Y.; Gunther, C.; Laurent, D.; Unger, C. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J. Cancer, 2005, 41, 1291-1299.
88. Fuse, E.; Tanii, H.; Kurata, N.; Kobayashi, H.; Shimada, Y.; Tamura, T.; Sasaki, Y.; Tanigawara, Y.; Lush, R. D.; Headlee, D.; Figg, W. D.; Arbuck, S. G.; Senderowicz, A. M.; Sausville, E. A.; Akinaga, S.; Kuwabara, T.; Kobayashi, S. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res., 1998, 58, 3248-3253.
89. Sparreboom, A.; Nooter, K.; Loos, W. J.; Verweij, J. The (ir)relevance of plasma protein binding of anticancer drugs. Neth. J. Med., 2001, 59, 196-207.